The Duke University Cancer Center earned its reputation for excellence with a multi-discipline approach to both its research and the treatment of patients.
Pleural and Lung Cancer
Excellence in Research
20+ Years of Experience
Since coming to Duke in 1996, Harpole has focused on the treatment of non-small cell lung cancer and esophageal cancer, as well as the creation of databases for the Duke Thoracic Oncology Program.
We can help you or a loved one get in contact with Dr. Harpole Jr. and find the treatment that's best for you.Get Started Today
Harpole’s contribution to mesothelioma and lung cancer research includes evaluation of treatment procedures, experimentation with biomarkers and management of the staging process. He has worked alongside experts in the field to publish studies that assist in understanding this complex diagnosis.
One study by Harpole and his colleagues focused on radiation for patients with malignant pleural mesothelioma. The study was conducted by analyzing records of patients who received extrapleural pneumonectomies and radiation at Duke University Medical Center from 2005 to 2010. By increasing experience they were better able to plan intensity-modulated radiation therapy (IMRT) tailored to individual patients.
A study of 913 patients revealed that the utility of protein biomarkers is currently restricted by available technology. Although scientists have made some improvement in studying biomarkers, there is still work to be done. In response to whether this goal of using technology to measure biomarkers has been met, Harpole says, “It’s close. It’s much better, and the good news is that we have all this material banked, so it’s available when the right machine comes around. . . . Hopefully in 2013 or 2014 the answer will be yes.”
Harpole and several colleagues conducted a study of new imaging techniques for chest cavity abnormalities. They proposed that positron emission tomography (PET) scans fused with computed tomography (CT) scans could better recognize and locate abnormalities. The results of their study confirmed this hypothesis, providing a way for better staging of diseases like lung cancer mesothelioma.
David Sugarbaker, M.D, a heralded expert in mesothelioma and thoracic surgery, has conducted research with Harpole. Sugarbaker and Harpole worked with other physicians to evaluate the treatment of mesothelioma patients at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Their study, published in 1996, produced guidelines for revising the current mesothelioma staging system, which measures the severity of cancer, determines appropriate treatment and informs prognosis.
In addition to his teaching positions at Duke, Harpole serves as the director of the Lung Cancer Prognostic Research Laboratory. He also is the chief of Cardiothoracic Surgery at Durham VA Medical Center in nearby Durham, North Carolina.
He is certified by both the American Board of Surgery and the American Board of Thoracic Surgery. He is a member of the American Society of Clinical Oncology. He is Co-chair of the National Cancer Institute’s Thoracic Malignancy Steering Committee.
Harpole encourages future doctors to show a similar level of care and expertise as he holds the position of Duke Surgery’s Vice Chair of Faculty and Education, with a goal of promoting hands-on surgical skill practices in a special education laboratory for students, physicians and residents.
Harpole has authored or contributed to more than 90 surgical articles discussing topics from prognosis to risk factors and patient selection. His works appear in journals such as the Annals of Thoracic Surgery and the European Journal of Cardiothoracic Surgery.
Disclaimer: Dr. David H. Harpole Jr. has no professional affiliation with Asbestos.com.
Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers. Read More